API | coltuximab ravtansine

coltuximab ravtansine Report issue

Biologics mAb ADC Experimental

AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW

ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
coltuximab ravtansine

More Chemistry

Pharmacology

Mechanisms of Action:
- B-lymphocyte antigen CD19 (Homo sapiens) ^UniProt
- B-lymphocyte antigen CD19 (Homo sapiens) ^UniProt
Multi-specific: No
Payload: maytansinoid
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

coltuximab ravtansine | sar3419 | sar 3419 | sar-3419

Organizations (2)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Lymphoma (Phase 1)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Non-Hodgkin (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 5
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue